Decision

Early access to medicines scheme (EAMS) scientific opinion: nivolumab for renal cell carcinoma

This publication was withdrawn on

The EAMS opinion for nivolumab for renal cell carcinoma has been withdrawn as the marketing authorisation has been adopted by the European Commission.

Information on the EAMS scientific opinion given to nivolumab for renal cell carcinoma (RCC), including the public assessment report.